期刊文献+

探讨血清促甲状腺素与甲状腺癌的发病关系 被引量:4

The relationship between serum thyroid stimulating hormone and thyroid cancer
下载PDF
导出
摘要 目的探讨甲状腺癌的病理发病与促甲状腺激素(TSH)水平的相关性。方法选取450例2014年8月~2016年8月间我院收治的甲状腺患者作为本组研究对象,分析患者的性别、年龄、淋巴结情况、肿瘤情况、治疗前后实验室检查结果,探讨TSH水平与甲状腺癌的发病关系。结果甲状腺组患者TSH水平显著高于良性肿瘤组(P〈0.05);TSH水平与患者病灶直径、肿瘤分期、淋巴结转移及包膜侵犯呈显著性相关关系(P〈0.05),但TSH水平与患者年龄、性别、肿瘤数及血管侵犯无显著相关性;甲状腺癌患者高TSH水平例数显著升高(P〈0.05)。结论血清中TSH水平与甲状腺癌的发生与发展密切相关,并与患者淋巴结转移、肿瘤分期密切相关,且较高的TSH水平可增强甲状腺癌的患病风险。 Objective To investigate the correlation between the incidence of thyroid carcinoma and TSH, and to provide evidence for clinical application.MethodsSelect 450 cases of patients with thyroid from August 2014 to August 2016 in our hospital as the object of study in this group, the analysis of gender and age of patients, lymph nodes, tumor, laboratory examination results, to explore the relationship between TSH levels and thyroid cancer.ResultsThyroid patients with TSH was significantly higher than that in benign tumor group (P〈0.05);the level of TSH and patients with lesion diameter, tumor stage, lymph node metastasis and capsule invasion was significantly correlated (P〈0.05), but the level of TSH and age, gender, tumor number, vascular invasion and no significant correlation;TSH the level of thyroid cancer patients were significantly increased (P〈0.05).ConclusionThe level of TSH in serum is closely related to the occurrence and development of thyroid cancer, and is closely related to lymph node metastasis and tumor stage, and the higher TSH level can increase the risk of thyroid cancer.
作者 李海红 曹诗红 郭艳宏 LI Hai-hong CAO Shi-hong GUO Yan-hong(Department of Internal Medicine, Zhoushan Second People's Hospital, Zhoushan 316000, China)
出处 《中国生化药物杂志》 CAS 2017年第5期44-46,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 促甲状腺素 甲状腺癌 promote the thyroxine thyroid cancer
  • 相关文献

参考文献5

二级参考文献47

  • 1贾福军,张海燕,郭新胜,李鹤展.抑郁症患者的甲状腺功能和细胞因子的研究[J].上海精神医学,2004,16(5):277-279. 被引量:12
  • 2沈渔邨.精神病学[M].5版.北京:人民卫生出版社,2012:880-894.
  • 3Sawicka-Gutaj N, Klimowicz A, Sowinski J, et al. Pyramidal lobe de- creases endogenous TSH stimulation without impact on radio-iodine therapy outcome in patients with differentiated thyroid cancer[ J ]. Ann Dendocrinol (Paris) ,2014,75 ( 3 ) : 141-147.
  • 4Papaleontiou M, Haymart MR. New insights in risk stratification of dif- ferentiated thyroid cancer[ J]. Curr Opin Onco1,2014,26 ( 1 ) : 1-7.
  • 5McLeod DS. Thyrotmpin in the development and management of differ- entiated thyroid cancer[ J]. Endocrinol Metab Clin North Am,2014, 43(2) :367-383.
  • 6Kim H J, Lee JI, Kim NK, et al. Prognostic implications of radioiodine avidity and serum thyroglobulin in differentiated thyroid carcinoma with distant metastasis [ J ]. World J Surg,2013,37 ( 12 ) : 2845-2852.
  • 7Kim HK, Yoon JH, Kim S J, et al. Higher TSH level is a risk factor for differentiated thyroid cancer [ J ]. Clin Endocrinol (Oxf) , 2013,78 ( 3 ) :472-477.
  • 8Pitoia F, Marlowe RJ, Abelleira E, et al. Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone with- drawal in patients with high-risk differentiated thyroid cancer [ J ]. J Thyroid Res ,2012,2012:481568.
  • 9Malandrino P, Latina A, Marescalco S, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin [ J ]. J Clin Endocrinol Metab, 2011,96 ( 6 ) : 1703-1709.
  • 10Middendorp M, Grunwald F. Update on recent developments in the therapy of differentiated thyroid cancer [ J ]. Semin Nucl Med, 2010, 40(2) :145-152.

共引文献88

同被引文献43

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部